Bupropion decreases plasma levels of asymmetric dimethylarginine and ameliorates renal injury by modulation of Ddah1, Oatp4c1, Oct2, and Mate1 in rats with adenine-induced chronic renal injury
- PMID: 40474975
- PMCID: PMC12138378
- DOI: 10.3389/fphar.2025.1565713
Bupropion decreases plasma levels of asymmetric dimethylarginine and ameliorates renal injury by modulation of Ddah1, Oatp4c1, Oct2, and Mate1 in rats with adenine-induced chronic renal injury
Abstract
Objective: The objective of the study was to investigate whether bupropion (BUP) or its circulation metabolites could decrease plasma level of asymmetric dimethylarginine (ADMA) and ameliorate renal injury by modulation of Ddah1, Oatp4c1, Oct2, and Mate1 in rats with adenine-induced chronic renal injury.
Methods: The study initially determined the effect of BUP and its metabolites on cell viability and apoptosis in HK2 cells in the presence and absence of ADMA. Secondly, the study explored whether long-term administration of BUP could reduce the plasma level of ADMA and mitigate renal damage. Thirdly, the expression and activity of Oct2, Ddah1, Mate1 and Oatp4c1 was determined by Western blot and UPLC-MS/MS.
Results: With 0.5 μmol/L ADMA, hydroxybupropion (HBUP, 100 nmol/L), threo-hydrobupropion (TBUP, 10 nmol/L and 1 μmol/L) reduced N-Acetyl-β-D-glucosidase (NAG) level. At 5 μmol/L ADMA, BUP (1 nmol/L-1 μmol/L), HBUP (1-100 nmol/L), and BUP cocktail enhanced survival. At 50 μmol/L ADMA, HBUP (10 nmol/L and 1 μmol/L), TBUP/erythro-hydrobupropion (EBUP) (10-100 nmol/L), and BUP cocktail stimulated survival. EBUP (1 and 100 nmol/L) lowered LDH. BUP (100 nmol/L) and TBUP (1 μmol/L) decreased NAG. TBUP (10 nmol/L, 1 μmol/L) and EBUP (100 nmol/L) inhibited apoptosis. In adenine-induced chronic renal injury rats, long-term administration of BUP significantly decreased the serum concentration of ADMA and creatinine by 12.78% and 38.85%, respectively, ameliorated interstitial lesions and fibrosis and upregulated Ddah1, Oatp4c1, Oct2, Mate1. BUP increased metformin renal clearance without affecting digoxin disposition.
Conclusion: Bupropion moderately decreases plasma levels of ADMA and ameliorates renal injury by modulation of Ddah1, Oatp4c1, Oct2, and Mate1.
Keywords: asymmetrical dimethylarginine; bupropion and its metabolites; chronic renal injury; metabolism enzyme; renal transporters.
Copyright © 2025 Huang, Xiao, Han, Yu, Zheng, Fang, Li, Liu, Xia, Zhang and He.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures











Similar articles
-
Mechanism of an unusual, but clinically significant, digoxin-bupropion drug interaction.Biopharm Drug Dispos. 2014 Jul;35(5):253-63. doi: 10.1002/bdd.1890. Epub 2014 Mar 3. Biopharm Drug Dispos. 2014. PMID: 24436229
-
Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1).Amino Acids. 2013 Oct;45(4):989-1002. doi: 10.1007/s00726-013-1556-3. Epub 2013 Jul 18. Amino Acids. 2013. PMID: 23864433
-
The renal transport protein OATP4C1 mediates uptake of the uremic toxin asymmetric dimethylarginine (ADMA) and efflux of cardioprotective L-homoarginine.PLoS One. 2019 Mar 13;14(3):e0213747. doi: 10.1371/journal.pone.0213747. eCollection 2019. PLoS One. 2019. PMID: 30865704 Free PMC article.
-
Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.J Am Soc Nephrol. 2015 Dec;26(12):3045-59. doi: 10.1681/ASN.2014030280. Epub 2015 Apr 8. J Am Soc Nephrol. 2015. PMID: 25855779 Free PMC article.
-
Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.Nitric Oxide. 2018 Aug 1;78:113-120. doi: 10.1016/j.niox.2018.06.004. Epub 2018 Jun 19. Nitric Oxide. 2018. PMID: 29928990 Free PMC article. Review.
Cited by
-
The Non-Traditional Cardiovascular Culprits in Chronic Kidney Disease: Mineral Imbalance and Uremic Toxin Accumulation.Int J Mol Sci. 2025 Aug 17;26(16):7938. doi: 10.3390/ijms26167938. Int J Mol Sci. 2025. PMID: 40869261 Free PMC article. Review.
References
-
- Alaoui A. C., Omari M., Quarmich N., Kouiri O., Chouhani B. A., Berraho M., et al. (2024). Prevalence and determinant factors of depression and anxiety in people with chronic kidney disease: a Moroccan cross-sectional study. Pan Afr. Med. J. 48, 15. 10.11604/pamj.2024.48.15.42881 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous